Key Insights

Highlights

Success Rate

70% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

22.6%

7 terminated out of 31 trials

Success Rate

69.6%

-16.9% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

50%

8 of 16 completed with results

Key Signals

8 with results70% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (9)
Early P 1 (3)
P 1 (6)
P 2 (9)
P 3 (1)

Trial Status

Completed16
Terminated7
Recruiting4
Withdrawn2
Unknown1
Active Not Recruiting1

Trial Success Rate

69.6%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT06928818RecruitingPrimary

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

NCT04855552Not ApplicableActive Not Recruiting

Telehealth Weight Loss Program for Breast Cancer Survivors

NCT05252390Phase 1Terminated

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT06085313Not ApplicableRecruitingPrimary

Cancer Pain Management Using a Web-based Intervention

NCT02476786Phase 2Recruiting

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

NCT03084536Phase 2Completed

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT05364450Not ApplicableCompleted

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

NCT06471673Phase 1Recruiting

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

NCT03007979Phase 2Completed

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT05584644Completed

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

NCT02642094Phase 2TerminatedPrimary

Aging Mammary Stem Cells and Breast Cancer Prevention

NCT01980823Early Phase 1Completed

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT04541225Phase 1Terminated

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

NCT05191004Phase 1Withdrawn

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

NCT05729451CompletedPrimary

Change in Cardiorespiratory Fitness and Breast Cancer Incidence and Mortality

NCT05133674Phase 2Unknown

Therapeutic Dose Monitoring (TDM) of Tamoxifen

NCT02907918Phase 2Terminated

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

NCT04400552Not ApplicableCompletedPrimary

Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients

NCT03494400Not ApplicableCompletedPrimary

Aerobic Training in Treatment for Breast Cancer

NCT02891681Not ApplicableCompleted

Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

Scroll to load more

Research Network

Activity Timeline